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ABSTRACT
Background Falls are a common cause of morbidity
and hospitalisation in older people. Inappropriate
prescribing and polypharmacy contribute to falls risk in
elderly patients. This study’s aim was to quantify the
problem and ﬁnd out if medication review in the
hospital setting led to deprescribing of medicines
associated with falls risk.
Methods Admissions records for elderly patients were
examined to identify those whose presenting complaint
included a fall. Inpatient medication charts,
pharmaceutical care notes, medical notes and discharge
summaries were examined to identify any falls-risk
medicines from admission histories and to determine if
any medication review took place, and whether or not
changes were made as a result. In particular
deprescribing and dose reduction details were analysed.
Results 100 patients over 70 years old were admitted
following a fall during the 2 months study period. The
mean number of medicines on admission was 6.8 per
patient with polypharmacy found in 62/100 (62%). One
or more falls-risk medicine was found in 65/100 (65%)
patients. Medicines review was carried out in 86/100
(86%) of patients, and 59/697 (8.5%) medicines were
deprescribed. Pharmacist involvement in medication
review led to a signiﬁcant reduction in the number of
falls-risk medicines per patient (p=0.002).
Conclusions Inappropriate prescribing and
polypharmacy are found frequently in elderly patients at
admission following a fall. Comprehensive medicines
reviews should be carried out in all such patients with
the objective of deprescribing or reducing doses to
minimise risk of harm. Involvement of a pharmacist
improves the rate of reduction of falls-risk medicines.
INTRODUCTION
Improving patient outcomes through medicines
optimisation is a national priority and a key part of
the work being undertaken by the National
Institute for Health Research Collaboration for
Leadership in Applied Health Research and Care
North West London (CLAHRC NWL) particularly
in older people who have frailty.
Falls in elderly patients are a common cause of
morbidity and an increasing reason for presentation
to hospital.1 With advancing age and frailty there is
increased chance of multimorbidity2 and prescrip-
tion of potentially inappropriate medicines, some
of which may contribute to risk of falls.3 Although
medications may be indicated at the time of diagno-
sis, they should be regularly reviewed as later they
may have more potential for harm and no longer
provide overall beneﬁt.3
Polypharmacy is independently associated with
negative outcomes in frailty particularly where
there is decline in nutritional status, functional
ability and cognitive capacity.4 Speciﬁcally, it has
been shown that it increases the risk of falls in
elderly populations and problematic polypharmacy
is therefore recognised as a potentially modiﬁable
contributing factor in falls and frailty.5
Freeland et al found that among patients aged
65 years and older who have experienced a fall in
the past year, the addition of each medication
above four increases their fall risk by 14%.6
Similarly, Damian et al found that each added
medicine increased physician-reported falls in the
preceding 30 days by 7%.7 These ﬁndings corrob-
orate earlier prospective cohort studies which have
shown that increasing medication use is associated
with increased falls-risk scores in elderly
patients.8 9
Further to this, the simultaneous discontinuation
of many drugs was found to be ‘safe’ and appears
to improve quality of life in elderly community
dwellers.10
Other studies demonstrate that multiple medica-
tion lists in elderly patients are more likely to
include falls-risk medicines. A systematic review
found that benzodiazepines, antidepressants, anti-
hypertensives and antipsychotics are among the
most common medicines to be prescribed to older
people with polypharmacy.11
A prospective cohort study of older adults
coming into hospital following a fall, found that
compared with robust elderly, those with frailty
were prescribed a signiﬁcantly higher number of
falls-risk medicines. The number prescribed on dis-
charge was additionally signiﬁcantly associated with
recurrent falls.12
The National Institute for Health and Care
Excellence (NICE) 2015 Quality Standard 86
includes the statement: ‘older people who present
for medical attention because of a fall should have
a multifactorial falls-risk assessment including car-
diovascular examination and a medication review’.1
Medication review has been deﬁned as ‘any sys-
tematic assessment of the pharmacotherapy of an
individual patient that aims to evaluate and opti-
mise patient medication by a change in prescription
either by a recommendation or by a direct
change’.13 As part of the wider CLAHRC project
on medicines optimisation in frailty, we deﬁned
levels of medication review in hospital14 (box 1).
Interim reviews can be doctor or pharmacist led
(especially as part of medicines reconciliation on
admission); the timing and breadth of the changes
are adjusted according to patient need with their
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immediate safety and well-being central to the decision but not
necessarily with their full knowledge or participation (in con-
trast to comprehensive review). Some reviews may lie between
the two categories so for ‘comprehensive’ we require the patient
to be involved (or their carer if capacity is impaired) and a
senior clinician (doctor or pharmacist) to lead.
It is imperative, however, to acknowledge that a condition for
medication review is reliable medicines reconciliation at admis-
sion and discharge from hospital.15 Any review process typically
begins with conﬁrmation of a patient’s current medication; if
inaccurate, decisions may be made based on the wrong informa-
tion.16 Therefore, prescribing and deprescribing is safe only in
the context of a full understanding of the patient’s drug history.
In order to support clinicians in reducing potentially inappro-
priate prescriptions (PIP) and optimise therapy, a PIP list for
older patients was developed locally17 directly from the
STOPP criteria of O’Mahony et al3 (see online supplementary
appendix A). From this we further developed a deprescribing
support tool ‘STOPIT’, used previously in an earlier
version.18 19 The tool includes a section on medicines known to
contribute to falls, commonly through orthostatic hypotension
and sedation.3 These falls-risk medicines are listed in box 2.
Opioids are included as they are linked with falls through sed-
ation and confusion, particularly in the vulnerable elderly.20 21
All medicines with anticholinergic properties or side effects are
implicated in falls and are therefore included in our list of
‘falls-risk medicines’22 23 (see box 2).
Other medicines may indirectly induce falls through mechan-
isms including vasovagal syndrome, carotid sinus hypersensitiv-
ity, bradycardia, tachycardia, periods of asystole24 and
hypoglycaemia. These medicines are not on our deﬁnitive list
for falls risk but their effects, risks and beneﬁts in vulnerable
patients are considered in a comprehensive review.
Aims and objectives
Our aim was to identify patients affected by falls, and ﬁnd
whether medication review in the acute setting led to depre-
scribing of falls-risk medicines.
Speciﬁc objectives were to:
▸ Identify all admissions aged over 70 years following a fall, on
polypharmacy or problematic medicines.
▸ Examine hospital clinician involvement in medication review.
▸ Quantify nature and extent of deprescribing.
Ethical approval
Ethics approval was not required for this work as it is part of
a service evaluation and improvement project. An ethics
waiver was granted by Chelsea and Westminster Hospital NHS
Foundation Trust Research and Development lead and National
Research Ethics Service (NRES).
Setting
The study was conducted at Chelsea and Westminster Hospital,
London (CWH) supported by CLAHRC NWL. Across all spe-
cialties, CWH admits an average of 740 adults a month,
approximately 500 of whom are 70 years and older.
METHODS
Admissions coding data and emergency department discharge
summaries (DSUMs) for the period 02 February 2015 to 31
March 2015 were examined to identify patients who were aged
70 years or older who were known to have had a fall and were
in hospital as a result overnight. Recruited patients were fol-
lowed-up prospectively, and data obtained from medical records
and electronic prescribing records. All patients were seen by
their usual pharmacist during their regular visits to the ward.
Screening of prescriptions and documentation of pharmaceutical
care contributions were undertaken as per ward pharmacy
inpatient standard procedures. Weekly consultant ward rounds
were attended by pharmacists as part of routine practice. No
speciﬁc research interventions were made, however, all pharma-
cists were aware of the project through departmental teaching
sessions aimed at improving communications regarding medica-
tion changes.
Final DSUMs were checked retrospectively for documentation
of medication reviews and any changes made to regular
medicines.
All data was collated by research student (AR) supervised by a
specialist pharmacist (EW).
A database was created for this cohort including details of the
following:
▸ Medicines reconciliation on admission veriﬁed as ‘reliable’ by
a pharmacist according to local policy.
▸ Medicines review documented as having taken place and by
whom.
▸ Pharmacist role in any medication review or change.
Box 1 CLAHRC NWL deﬁnitions of ‘medication review’
levels14
Comprehensive medication review
▸ This is a full review using a structured critical examination of
all current medication with the objective of reaching an
agreement with the patient about continuing treatment. The
reviewer systematically considers the beneﬁts and risks of
different medications, stops inappropriate medicines and
starts others.
Interim medication review
▸ In the acute hospital setting, reviews leading to short-term
medication changes frequently take place; these we have
deﬁned as interim. Medicines are reviewed when a patient
presents acutely unwell at hospital or when their condition
deteriorates or improves. Individual medicines may be
changed or held because they are considered ‘non-essential’
or currently ‘unnecessary’ or as part of the preoperative
assessment process. In addition in these settings, medicines
are stopped if they are identiﬁed as contributing to
morbidity.
Box 2 Falls-risk medicines (adapted from O’Mahony et al3)
▸ Antimuscarinics/anticholinergics and those with
anticholinergic side effects, for example, amitriptyline,
chlorphenamine, loperamide.
▸ ACE inhibitors and angiotensin receptor blockers.
▸ α blockers.
▸ Antipsychotics.
▸ Benzodiazepines and ‘Z drugs’.
▸ Calcium channel blockers.
▸ Long acting nitrates.
▸ Vasodilator antihypertensives used in heart failure.
▸ Opioids.
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▸ Changed doses and formulations.
▸ Newly prescribed medicine(s) and indication.
▸ Deprescribed and held medicine(s) and whether potentially
contributed to the risk of falls (box 2).
Medicines purchased over the counter for acute use ‘as
required’ were not included as regular medication. Neither were
acute courses of, for example, antibiotics and simple (non-
opiate) analgesia.
We deﬁne polypharmacy as the prescription of six or more
regular medicines as used by other researchers.25 ‘Appropriate’
polypharmacy requires that all medicines have a clear indication
and are not PIPs.17
Descriptive statistics were performed and falls-risk medicines
prescribed before and after review were compared using the
Kruskal-Wallis test for signiﬁcant difference in rank.
RESULTS
Identiﬁcation of patients with a history of falls
The total number of admissions to CWH for patients aged 70
or over during the study period was 1020, of whom 126 (12%)
were identiﬁed having presented following a fall. Of these
patients, 26/126 (21%) were ‘lost to follow-up by pharmacists’
as they were discharged from the Emergency Observation Unit
without a prescription or other identiﬁable documentation
about medication.
The remaining 100 were included in the analysis: the mean
age was 85 years, the oldest was 101 years old; 61/100 (61%)
were female. One patient was recorded as having an additional
falls admission within the project period.
Medications reconciliation and review
Medicines reconciliation was reliable on admission for 80/100
(80%); 3/100 (3%) patients were not on any regular medication
from admission through to discharge and 4/100(4%) patients
died during the inpatient episode.
Medication review was documented as having taken place
with or without changes to regular medicines in 86/100 (86%).
Fifty-eight (58% of patients) of these medication reviews were
comprehensive; in ﬁve (5%) cases there is documentation
regarding pharmacist reconciliation and review but not by the
doctor and in two (2%), the doctor documented ‘review’ but
the pharmacist had not completed medicines reconciliation on
admission. In the remaining 21/86 documented ‘reviews’ the
involvement of the patient or their carer is not clear. These were
noted as interim reviews.
Prevalence of polypharmacy
In total, 679 medicines were taken by 100 patients before any
medication review took place, a mean of 6.8 per patient (range
0–18, including unconﬁrmed medications).
Polypharmacy was present in 62/100 (62%) patients, and
problematic polypharmacy (the patient was taking at least one
medication identiﬁed as potentially inappropriate) was found in
57/62 (92%) of those with polypharmacy; or 57/100 (57%) of
all patients. Fifty-ﬁve out of 62 (89%) polypharmacy admissions
had a documented medication review.
Polypharmacy was found in more patients at discharge than at
admission in the cohort of 100: while 5/62 (8%) polypharmacy
patients were no longer on six or more medicines after review,
9/38 (24%) non-polypharmacy patients returned home with six
or more medicines: thus 66/100 (66%) patients were discharged
from hospital with polypharmacy. Bisphosphonates and vitamin
D accounted for 49/54 (91%) of the newly prescribed
medicines.
Falls-risk medications
One hundred and twelve out of 679 (16.5%) admission medi-
cines were falls-risk medicines taken by 65 patients (table 1):
30/112 (26.7%) of falls-risk medicines were reduced or
stopped. A Kruskal-Wallis test is used to ﬁnd a signiﬁcant reduc-
tion (p=0.004) in number of falls-risk medicines on these
patients’ prescriptions postreview (91) compared with at admis-
sion (112).
Of the 65/100 (65%) patients found to be on a falls-risk
medicine, 29/65 (45%) had no reduction in medication includ-
ing 12/65 (18%) who had no documented medicines reconcili-
ation. Six out of 65 (9%) did have a review and no changes
were made to falls-risk medicines; other prescription items were
started or doses increased in these cases. Twenty-three out of 65
(35%) patients had a comprehensive review which led to reduc-
tion of falls-risk medicines and 5/65 (8%) were no longer on
any by discharge.
Medication changes
Overall, 38/100 (38%) patients had their regular prescriptions
reduced in some way while in hospital. A total of 75/697
(10.8%) medicines were affected: 59/697 (8.5%) of all medi-
cines were deprescribed, 12/697 (1.7%) were reduced to a
lower dose and 4/697 (0.6%) medicines were held pending
further review (table 2).
Of these changed medicines, 29/75 (39%) were falls-risk
medicines in 21 patients (table 2). However, while there was a
decrease in falls-risk medicines following review, after changes
were made to regular medicines in hospital there was a net
increase to 733 in the total number of medicines prescribed for
the cohort. A list of all medicines deprescribed is in online sup-
plementary appendix B.
Pharmacist involvement
Pharmacists were involved in 45/86 (52%) cases where it was
documented that a medication review had taken place (with or
without changes made). The number of falls-risk medicines
decreased by a mean of 0.53 per patient before and after review
in these 45 (not including the dose reductions). A Kruskal-Wallis
test ﬁnds a signiﬁcant reduction between the numbers before
and after review (p=0.002). Of note, in all cases where medica-
tion review led to a reduction in falls-risk medicines for a
patient a pharmacist was involved and the changes were
documented.
Table 1 Medicines taken by elderly falls patients
n=100 patients
On
admission
At
discharge* Difference
No. of regular medicines 679 733 +54
No. of FRM 112 91 −21
(p=0.004)
Patients on ≥1 FRM 65 60 −5
% of all medicines that are FRM 16.4% 12.4% −4%
Mean FRM/patient reviewed n=82 1.19 0.939 −0.26
Mean FRM/patient reviewed with
pharmacist involved n=45
1.44 0.91 −0.53
(p=0.002)
FRM per patient not reviewed
n=18†
0.77 0.77 0
*Including four patients who died in hospital.
†Includes three patients on no medicines from admission through to discharge
therefore not reviewed in this context.
FRM, falls-risk medicine.
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DISCUSSION
A fall, whether or not an injury is sustained, is a common reason
for patients aged 70 or older to present to hospital. We identiﬁed
126 patients in a period of 2 months who were admitted (for at
least one night) from a total of 1020 admissions recorded in this
age group during this time (12%). We followed-up a cohort of
100, 97 of whom were on regular medication from admission.
Polypharmacy, deﬁned as six or more medicines was prevalent
(62%) with an average of 6.8 per patient. In just ﬁve polyphar-
macy patients, all medicines were considered appropriate in the
context of their age and history of falls.
We identiﬁed problematic polypharmacy in 57% of our
cohort (inpatients over 70 years old who had fallen prior to
admission). PIPs have previously been estimated to occur in
about a third of older patients.26 27 Our identiﬁed PIPs included
all anticholinergics, known to contribute to falls but we would
argue many medicines are unrecognised as being in this cat-
egory. We note one small study of anticholinergic burden and
falls identiﬁed regular anticholinergic prescriptions in 22% of
patients,28 and using their criteria only 10% of patients had no
identiﬁed risk of falls from their medicines. We used a shorter,
evidence-based list of falls-risk medicines, though inclusive of all
anticholinergics and found 65% of our patients on one or
more. The association of anticholinergics with falls has been
reafﬁrmed in a community study in men over 65 years.29
Despite the increase in the number of polypharmacy patients
(nine more at discharge than on admission), we have shown that
review improved prescribing and optimised medicines overall.
The increase was due largely to the prescribing of calcium and
vitamin D supplementation in our cohort; these additional med-
icines are considered appropriate according to the STOPP/
START criteria3 although an alternative view is emerging which
may lead to further consideration of local guidelines.30
The NICE pathway on falls in older people recommends that
those on ‘psychotropic’ medicines should have their medication
reviewed, with a specialist input if appropriate, and discontin-
ued if possible to reduce their risk of falling.1 We did not
include all medicines affecting mood; only antipsychotics, ben-
zodiazepines and ‘z-drugs’ which are considered directly linked
with falls. We may therefore need to update our list (box 2); if
we had included all psychotropics the number of falls-risk medi-
cines on admission in our study would be increased by 16 to a
total of 128.
A study by Browne et al and colleagues in 2014 looked at 50
inpatients at risk of falls and found that only 20% of falls-risk
medicines were suitable for change after reviews, which were
found to be time and resource intensive.31 However, the
authors suggest targeting resources to those on polypharmacy
(four or more in their study) including as required (prn) rather
than restricting to ‘regular’ medications results in greater depre-
scribing rates.31 Another study demonstrated that the risk of
subsequent falls is reduced in patients for whom falls-risk medi-
cines are reduced,32 suggesting that it is an effective use of
resource if the medical cost of a fall is taken into account.
We have put in place speciﬁc tools to prompt safe, patient-
centred deprescribing when falls-risk medicines are identiﬁed
and although we did not measure their uptake and use in this
project, we are further promoting STOPIT and teaching about
PIPs to junior staff. We believe pharmacists can and should be
more proactive in stopping medicines33 and such tools encour-
age and promote good prescribing practice. This is supported
by our ﬁnding that suggests pharmacist involvement in medica-
tion reviews signiﬁcantly reduces the number of falls risk medi-
cines. However, the mean reduction in number was less than
one drug (0.53) per patient. The beneﬁt in terms of reducing
falls is unclear but there are other beneﬁts of stopping medi-
cines, such as decreased pill burden and costs. We plan to
measure these with follow-up of a larger cohort, also checking
for readmissions and further falls over a longer period.
Our recommendation is to involve pharmacists in identifying
patients at risk, beginning the process of comprehensive medica-
tion review from the point of verifying the drug history (in line
with Royal Pharmaceutical Society standards34) and prompting
the prescriber at all stages of the patient journey through the
hospital and at transfer. For this we may need to improve
knowledge and understanding of anticholinergic medicines and
switch patients’ prescriptions to lower anticholinergic burden
when they are at risk of falls (or confusion).35 In addition, we
would explore ways in which the electronic prescribing record
system could alert to the need for a medicines review following
medicines reconciliation documentation as described by
Graabaek et al.36
Limitations
The period of study was February and March 2015. These
months may not be typical; seasonal variation in falls rates is
likely. However, prescribing of falls-risk medicines is not
expected to vary with time of year.
It is unclear if the number of reviews documented is a true
reﬂection of the number actually carried out on elderly patients
admitted following a fall. Reviews without changes being made
are under-represented.
Table 2 Falls-risk medicines deprescribed, held or reduced
Patient Medicine
Deprescribed (D)
Held (H)
Reduced dose (R)
1 Tramadol D
2 Fentanyl D
3 Lercanidipine
Losartan
D
D
4 Ramipril D
5 Buprenorphine
Doxazosin
D
R
6 Buprenorphine D
7 Lercanidipine
Lisinopril
Moxonidine
D
D
D
8 Tramadol D
9 Isosorbide mononitrate D
10 Ramipril D
11 Tolterodine D
12 Losartan
Tramadol
D
D
13 Amlodipine D
14 Amitriptyline
Isosorbide mononitrate
Ranolazine
D
D
D
15 Oxybutynin D
16 Diazepam D
17 Ramipril R
18 Lisinopril D
19 Irbesartan H
20 Cetirizine
Amlodipine
D
H
21 Zopiclone D
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Only regular medicines meant for long-term continuation
were included in our analysis. We, therefore, excluded acute use
of several contributors to falls risk, for example, sedating anti-
histamines, if they were as required medicines. Further to this
our deﬁnitive falls-risk medicine list was limited to those with
evidence linking them to actual falls. Other antihypertensive
medicines such as β-blockers are implicated, for example, if the
patient experiences a postural drop in blood pressure; there is a
case for extending our list to include these in line with other
published data.37
CONCLUSION
Inappropriate prescribing and polypharmacy are found fre-
quently in elderly patients at admission following a fall.
Comprehensive medicines reviews should be carried out in all
such patients with the objective of deprescribing or reducing
doses to minimise risk of harm. This is signiﬁcantly more likely
to be achieved with a pharmacist input. We suggest involving
pharmacists in reviews from the start of medicines reconciliation
at admission (earlier where possible), improving recognition of
falls-risk medicines by all clinicians and supporting prescribers
in deprescribing.
What this paper adds?
What is already known on this subject?
▸ Anticholinergic, sedative and hypotensive medicines increase
risk of falls in elderly patients.
▸ Falls are a common reason for admission to hospital in older
people and an increasing burden on healthcare services.
▸ Polypharmacy is associated with negative outcomes in
frailty.
What this study adds?
▸ Medicines known to contribute to falls risk are taken by
65% of elderly patients admitted to hospital locally
following a fall.
▸ Problematic polypharmacy is a common ﬁnding in those
over 70 years old.
▸ Following review of medication particularly where a
pharmacist makes a contribution, deprescribing leads to a
signiﬁcant reduction in prescriptions for falls-risk medicines.
Twitter Follow Emily Ward at @emward_pharm
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